Immix Biopharma (IMMX) Net Cash Flow (2021 - 2026)

Immix Biopharma has reported Net Cash Flow for 6 years, with the latest figure at -$14.7 million in Q1 2026.

• Quarterly Net Cash Flow fell 736.67% year-over-year to -$14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.2 million (up 564.44% YoY) and the FY2025 annual result came in at $76.2 million, up 43272.74% from the prior year.
• Net Cash Flow slipped to -$14.7 million in Q1 2026 per IMMX's latest filing, from $78.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $78.0 million in Q4 2025 and troughed at -$14.7 million in Q1 2026.
• A 5-year average of $3.6 million and a median of -$1.8 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 2016.24% in 2022, then soared 4032.39% in 2025.
• Over 5 years, Net Cash Flow stood at -$3.5 million in 2022, then soared by 39.54% to -$2.1 million in 2023, then rose by 5.73% to -$2.0 million in 2024, then jumped by 4032.39% to $78.0 million in 2025, then plunged by 118.8% to -$14.7 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$14.7 million, $78.0 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.